Investigation of the safety and efficacy of the optimized measles virus vaccine in bladder tumor healing

Phase 1 clinical trials of Trial of Intravesical Measles Virotherapy in Patients With Bladder Cancer

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

IRCT

Registry ID

IRCT20230903059342N1

Enrollment

Registered

2023-10-17

Start date

2023-09-23

Completion date

Unknown

Last updated

2023-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bladder Cancer. Malignant neoplasm of bladder

Interventions

Intervention 1: They include patients who receive the optimized measles vaccine product in addition to the standard treatment. Intervention 2: Control group: Patients who receive only standard treatme

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Bladder Cancer has been confirmed. The patient should be diagnosed by a urologist. It is not possible to remove the bladder for the patient. The age of the patient must be above 18 years The patient should not be pregnant. The patient's Karnofsky performance score (KPS) should be more than 50% (the patient is not disabled and does not need special assistance and care). The ability to understand and sign the consent form including the patient and one of these cases: the patient's spouse, parent. Ability to provide informed consent Be willing to comply with all required protocol steps, including providing biological samples and returning to the clinical study site for subsequent visits. Adequate performance status for treatment in the opinion of the enrolling urologist, including adequate hematological, liver, and renal function Must be willing to use contraceptive methods during the study.

Exclusion criteria

Exclusion criteria: Severe or life-threatening acute infection A history of not following the doctor's treatment orders Use of drugs that weaken the immune system Having diseases that disrupt the immune system History of organ transplantation Allergy to measles vaccine pregnancy Concomitant use of other investigational treatments Disease to other cancers such as skin that have not been fully treated.

Design outcomes

Primary

Measure	Time frame
Re-observation of bladder tumor by cystoscopy. Timepoint: Three months. Method of measurement: Cystoscopy examination of the bladder.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactRuhollah Dorostkar

Bagheiat-allah University of Medical Sciences

R.dorost@yahoo.com+98 21 8817 0179

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026